Wolfe Research upgraded Celldex (CLDX) to Outperform from Peer Perform with a $44 price target The firm sees a better catalyst setup for the shares in 2026 relative to 2025. Investors may respond better to Celldex’s catalysts this year given the stock’s “depressed valuation,” the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex price target raised to $34 from $30 at Goldman Sachs
- Celldex: Barzolvolimab’s Durable Efficacy in Chronic Urticaria Underpins Buy Rating Ahead of Key Late-Stage Catalysts
- Celldex presents new data from Phase 2 ColdU, SD Open Label Extension
- Celldex price target raised to $44 from $43 at Morgan Stanley
- Celldex price target raised to $68 from $58 at Stifel